European Young Investigator Award 2026

Tawfeeq Shekh-Ahmad is an Associate Professor at the School of Pharmacy, the Hebrew University of Jerusalem. He received his PhD in Pharmaceutical Sciences from the same institution and subsequently completed postdoctoral training at the UCL Queen Square Institute of Neurology, where he investigated mechanisms underlying refractory epilepsy.

He established his independent laboratory in 2019 to study the biological basis of epileptogenesis and to develop disease-modifying therapies. His research focuses on molecular and redox-dependent pathways that drive epilepsy development and pharmacoresistance following brain injury, integrating oxidative stress biology, neuroprotective signaling, targeted drug delivery, and gene-therapy approaches.

Using advanced experimental models and translational methodologies, his group develops precision therapeutic strategies aimed at preventing epilepsy after neurological insults and modifying the progression of chronic epilepsy, with the long-term goal of shifting treatment from symptomatic seizure suppression toward disease modification and prevention.